After dropping -2.38% in the last session, Enzolytics Inc (OTCPINK: ENZC) closed the last session at $0.2010, bringing its market cap to $562.39M. Enzolytics stock recently traded 42.22M shares, higher than the average daily volume of 41.93M. In addition, the shares have traded between $0.1821 and $0.2289. There are 2.80 billion outstanding shares compared to a float of 1.88 billion.
As measured by performance, ENZC stock performed -27.44% last week and 57.40% last month. While the quarterly performance fell by 33.07 percent, the annual performance improved by 51.85 percent with a 215.05% six-month performance. ENZC stock prices ranged from $0.0002 – $0.9580 in the past 52 weeks. Despite announcing progress in clinical trials, ENZC stock dropped.
What was the purpose of those clinical trials?
Enzolytics is a pharmaceutical company dedicated to the development and commercialization of proprietary proteins and monoclonal antibodies to treat disease caused by debilitating infectious agents. A number of therapeutics are being developed by ENZC for the treatment of infectious diseases. Among the ENZC’s patented and clinically tested compounds, ITV-1 (Immune Therapeutic Vaccine-1) contains l-inactivated pepsin fraction (IPF) that has been shown effective in treating HIV/AIDS.
A strategy by Enzolytics to advance its previously tested anti-HIV therapeutic ITV-1 to clinical trials and widespread distribution in Europe has been finalized.
- ENZC will achieve a significant milestone for both human health and profitability when these steps are completed for its anti-HIV therapy.
- An anti-HIV therapeutic developed by ENZC earlier made progress toward Bulgarian Drug Agency (BDA) certification, however that process was interrupted before it was completed.
- A significant number of positive results from clinical trials were nevertheless documented during that period.
- ENZC has no doubt that the clinical trials under the European Medicines Agency (EMA) will similarly succeed as a result of these positive results
How ENZC will go through it?
International Medical Partners Ltd. (IMPL) was formed by Enzolytics (ENZC) and European-based partners. IMPL is owned equally by ENZC and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency including Russia and its ex-Soviet states.
For the initial production of ITV-1, ENZC engages Danhson Ltd., a Contract Manufacturing Company (CMO) for use in preparing the Best Methods Report for future production and clinical trial documentation.